Unsupported Price Hikes for Top US Drugs Drive $815 Million Spending Increase
Unjustified price hikes on five top US drugs, including Darzalex and Biktarvy, added $815 million to healthcare spending in 2023. ICER’s report reveals these increases lack clinical evidence of improved patient benefit, raising concerns about value.
Unsupported Price Hikes for Top US Drugs Drive $815 Million Spending Increase Read More »